Who makes Intravenous bumetanide TID?

Intravenous bumetanide TID is developed by Vrije Universiteit Brussel.

What development phase is Intravenous bumetanide TID in?

Intravenous bumetanide TID is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Intravenous bumetanide TID

Vrije Universiteit Brussel · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Intravenous bumetanide TID
Also known as	Burinex (brand name for bumetanide)
Sponsor	Vrije Universiteit Brussel
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Intravenous bumetanide TID CI brief — competitive landscape report
Intravenous bumetanide TID updates RSS · CI watch RSS
Vrije Universiteit Brussel portfolio CI